Abstract 437P
Background
Sarcopenia, characterized by a decline of skeletal muscle plus low muscle strength and/or physical performance, has emerged to be an important prognostic factor for advanced cancer patients. Sarcopenia is diagnosed if there is decreased muscle mass and either decreased muscle function or physical activity. The diagnostic tools for evaluating muscle mass in cancer patients was using muscle index derived from abdominal CT scan. However, the practicability of using CT scan for screening decreased muscle mass has been questioned. Until know there is limited data diagnostic value of Bio-impedance analysis (BIA) in cancer patients. The aim of this study is to know the correlation between BIA and abdominal CT scan to diagnose decreased muscle mass in cancer patients.
Methods
This cross-sectional study included adult cancer patients who underwent abdominal CT scans in purpose for diagnostic. BIA was performed in the same day when CT-scan was performed. CT-scans was analyzed using special software. BIA was performed using standing-posture 2-electrode BIA device BC-418 (BIA, Tanita Corp, Tokyo, Japan). Height adjusted appendicular skeletal muscle mass (ASM) was calculated from BIA. Height adjusted skeletal muscle Index (SMI) was performed from a single cross-sectional CT image (slice) at third lumbar (L3) for abdominal skeletal muscle area. We calculated Pearson’s r correlation coefficient between two parameters.
Results
A total of 39 patients were included. Twenty-eight (71.8%) patients were female. The mean of age was 51.18 +13.83 years old. Several type of cancer such as breast, lung, gastrointestinal and genitourinary cancer were included. Eleven (28.2%) patients were in advanced stage. Mean of height adjusted BIA was 6.60 + 0.98 kg/m2. Mean of height adjusted muscle mass was 42.25 + 7.57 cm2/m2. BIA and CT-derived muscle were moderately correlated (r = 0.72, p < 0.001).
Conclusions
This study showed that BIA- and CT-derived muscle mass was moderately correlated in adult cancer patients. Further research is needed to confirm this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract